News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Francois Clement Bidard

Articles by Francois Clement Bidard

TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC

ByDebasish Tripathy,Dejan Juric,Sonia Pernas,Francois Clement Bidard,Kevin Perraud,Louise Emmett,Ana Sofia Ferreira

June 22nd 2025

27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

ByAditya Bardia, MD, MPH, FASCO,Javier Cortés, MD,Francois Clement Bidard,Guillermo Streich,José García-Sáenz,Janice Lu, MD, PhD ,Giulia Tonini,Simona Scartoni,Alessandro Paoli,Alessio Fiascarelli,Alessandro Bressan,Monica Binaschi,Tomer Wasserman,Virginia Kaklamani, MD, DSc

June 19th 2025

9 Elacestrant (ELA) vs Standard-of-Care (SOC) in ER+/HER2–Advanced (adv) or Metastatic Breast Cancer (mBC) with ESR1 Mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

9 Elacestrant (ELA) vs Standard-of-Care (SOC) in ER+/HER2–Advanced (adv) or Metastatic Breast Cancer (mBC) with ESR1 Mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

ByAditya Bardia, MD, MPH, FASCO,Joyce O’Shaughnessy, MD,Francois Clement Bidard,Phillipe Aftimos,Javier Cortes,Janice Lu, MD, PhD ,Giulia Tonini,Kathy Puyana Theall,Alessandro Paoli,Virginia Kaklamani, MD, DSc

August 24th 2024

1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer

ByPhilippe Aftimos,Javier Cortes,Francois Clement Bidard,Virginia Kaklamani, MD, DSc,Aditya Bardia, MD, MPH, FASCO,Alberto J. Montero, MD, MBA, CPHQ,Joo Hyuk Sohn,Giulia Tonini,Krzysztof J. Grzegorzewski,Patrick Neven, MD, PhD

April 28th 2023

7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

ByAditya Bardia, MD, MPH, FASCO,Francois Clement Bidard,Patrick Neven, MD, PhD,Alberto J. Montero, MD, MBA, CPHQ,Joo Hyuk Sohn,Philippe Aftimos,Javier Cortes,Simona Scartoni,Nassir Habboubi,Virginia Kaklamani, MD, DSc

April 28th 2023

Latest Updated Articles

TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC
Published: June 22nd 2025 | Updated:

Trending on CancerNetwork

Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer

Enfortumab Vedotin Combo Improves Survival in Cisplatin-Eligible MIBC

SABCS 2025: The Top 5 Takeaways for Breast Cancer Research

FDA Grants Fast Track Designation to GPC3x4-1BB Bispecific Antibody in HCC

T-DXd Improves iDFS Across HER2+ Early Breast Cancer Subgroups